Physician profile
Casey Lambert
NPI 1063273605
$8,589.78
in general payments reported to CMS, 2019-2025
32 companies · $4,391 in 2025
The $4,391 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $4,199 · 2025: $4,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,589.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,580.08 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $733.39 | 2024-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $720.67 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $492.16 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $393.23 | 2024-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $309.14 | 2024-2025 | Xifaxan, Trulance, Plenvu |
| Teva Pharmaceuticals USA, INC. | $256.85 | 2024 | Austedo Xr, Simlandi |
| Ardelyx, INC. | $254.70 | 2024-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $242.53 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $242.29 | 2025 | Rezdiffra |
| Genzyme Corporation | $210.04 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $199.57 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $180.52 | 2025 | Dupixent |
| Medtronic, INC. | $150.92 | 2025 | Interstim |
| Exact Sciences Corporation | $145.18 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.65 | 2024 | Jardiance, Cyltezo |
| Novo Nordisk INC | $138.22 | 2025 | Wegovy |
| Organon LLC | $137.77 | 2025 | Vtama |
| Alexion Pharmaceuticals, INC. | $135.00 | 2025 | Strensiq |
| Kyowa Kirin, INC. | $120.73 | 2025 | |
| Merck Sharp & Dohme LLC | $120.21 | 2024 | Dificid |
| Actelion Pharmaceuticals US, INC. | $118.03 | 2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals Lp | $117.68 | 2025 | Tezspire |
| Lilly USA, LLC | $111.90 | 2024-2025 | Zepbound, Omvoh |
| Celltrion USA INC. | $106.76 | 2024-2025 | Vegzelma |
| Qol Medical, LLC | $61.14 | 2024-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $40.83 | 2025 | Zenpep |
| Evoke Pharma, INC. | $33.90 | 2024-2025 | |
| Biocon Biologics INC | $32.64 | 2025 | Hulio, Yesintek |
| Boston Scientific Corporation | $27.50 | 2024 | Hydra Jagwire |
| Braintree Laboratories, INC. | $19.31 | 2024 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $16.24 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.